BiotechTube

CAB-AXL-ADC + PD-1 inhibitor

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Small-Cell Lung Cancer

Conditions

Non-Small-Cell Lung Cancer

Trial Timeline

Mar 17, 2021 → Jul 9, 2025

NCT ID
NCT04681131

About CAB-AXL-ADC + PD-1 inhibitor

CAB-AXL-ADC + PD-1 inhibitor is a phase 2 stage product being developed by BioAtla for Non-Small-Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04681131. Target conditions include Non-Small-Cell Lung Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04681131Phase 2Completed
NCT03425279Phase 1/2Completed

Competing Products

20 competing products in Non-Small-Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Enzastaurin HCLEli LillyPhase 2
52
ALIMTA + CarboplatinEli LillyPhase 2
52
LazertinibYuhanPhase 1/2
41
CS-7017 + ErlotinibDaiichi SankyoPhase 1
33
Datopotamab Deruxtecan (Dato-DXd)Daiichi SankyoPhase 1/2
41
Raludotatug Deruxtecan + Ifinatamab Deruxtecan + Docetetaxel + 5-hydroxytryptamine subtype 3 receptor antagonist + Neurokinin-1 receptor antagonist + CorticosteroidDaiichi SankyoPhase 2
52
Pembrolizumab + Carboplatin + Paclitaxel + Pemetrexed + Vibostolimab + Boserolimab + MK-4830 + MK-0482 + Ifinatamab Deruxtecan (I-DXd) + HER3-DXdDaiichi SankyoPhase 1/2
41
CS-7017 + Carboplatin + PaclitaxelDaiichi SankyoPhase 1
33
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Gilteritinib + ErlotinibAstellas PharmaPhase 1/2
41
naquotinib + midazolamAstellas PharmaPhase 1
33
Tarceva + carboplatin + paclitaxelAstellas PharmaPhase 2
52
Tarceva (erlotinib HCl, OSI-774 )Astellas PharmaPhase 3
77
ASP3082Astellas PharmaPhase 2
52

Other Products from BioAtla

Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabPhase 2
44
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabPhase 2
44
CAB-AXL-ADC + PD-1 inhibitorPhase 1/2
33
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)Phase 1/2
33
CAB-ROR2-ADC + PD-1 inhibitorPhase 1/2
33